Anti-IgE Antibody Treatment for Multi-Allergen Desensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for food allergies and anaphylaxis, such as allergen avoidance and epinephrine administration, are inadequate, particularly for multiple food allergens and idiopathic anaphylaxis, with limited therapeutic options and significant medical need for safer and more effective therapies.
Innovation Solution
Administration of ligelizumab, a humanized monoclonal antibody with high affinity for IgE, to block IgE interactions with both high and low affinity receptors, reducing IgE levels and receptor expression, thereby desensitizing subjects to allergens and preventing allergic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If strict avoidance of allergens is implemented, then allergic reactions are prevented, but quality of life and dietary flexibility are severely limited
Solution Approach 1:
The patent introduces anti-IgE antibodies (such as omalizumab) as intermediary substances that mediate between the allergen and the immune system. These antibodies bind to IgE, preventing the allergen from triggering the allergic response, thereby allowing controlled exposure to allergens while maintaining safety.
Solution Approach 2:
The patent changes the immunological parameter by reducing serum IgE levels through anti-IgE antibody therapy. This parameter change allows the patient to tolerate allergens that would normally trigger severe reactions, enabling dietary flexibility while maintaining protection against anaphylaxis.
2Reliability
If epinephrine administration is used for anaphylaxis treatment, then life-threatening reactions are addressed, but it is reactive rather than preventive and requires frequent intervention
Solution Approach 1:
The patent implements preliminary action by administering anti-IgE antibodies before allergen exposure occurs. This preventive therapy reduces serum IgE levels and blocks IgE-receptor interactions in advance, preventing anaphylaxis before it occurs rather than treating it reactively after symptoms manifest.
Solution Approach 2:
The patent establishes continuity of useful action through maintenance therapy with anti-IgE antibodies administered at regular intervals. This continuous suppression of IgE levels provides ongoing protection against anaphylaxis, eliminating the need for repeated emergency interventions.
3Reliability
If allergen-specific oral immunotherapy is used, then desensitization to a single allergen is achieved, but it is not suitable for multiple allergens and has limited applicability
Solution Approach 1:
The patent achieves universality by using anti-IgE antibodies that non-specifically target IgE across all allergen types. This single mechanism provides protection against multiple food allergens (peanut, tree nuts, seafood, egg, milk, wheat, soy) and other allergens simultaneously, making it applicable to a broad range of patients with different allergy profiles.
4Reliability
If monoclonal anti-IgE treatment is administered, then IgE binding to receptors is blocked, but side effects ranging from skin inflammation to systemic anaphylaxis occur
Solution Approach 1:
The patent implements feedback by monitoring serum IgE levels and treatment response to adjust dosing. This allows optimization of the therapeutic effect while minimizing side effects, as the anti-IgE antibody dose can be modified based on the patient's IgE reduction response and tolerance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ligelizumab provides superior and sustained suppression of IgE, effectively reducing allergen sensitivity and preventing anaphylaxis, including idiopathic cases, with potential adjunct use in oral immunotherapy to enhance safety and efficacy.
Implementation Method 1
ligelizumab, a humanized monoclonal antibody with high affinity for IgE, to block IgE interactions with both high and low affinity receptors
Data Source
AI summary
The present disclosure relates to methods for modifying the course of a disease or disorder involving IgE, in particular an IgE mediated allergic reactions to one or more allergens, in subjects having such disease or condition.